Revolution Medicines, Inc.
RVMD
37 insider filings · Latest: Jun 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Mar 13 11:38 PM | Kelsey Stephen Michael | Proposed Sale | 3,901 | $99.59 | $388.5K | — | View → |
| Mar 16, 2026 | Mar 13 11:36 PM | Horn Margaret A | Proposed Sale | 4,722 | $99.59 | $470.3K | — | View → |
| Mar 16, 2026 | Mar 13 11:34 PM | GOLDSMITH MARK A | Proposed Sale | 13,261 | $99.59 | $1.3M | — | View → |
| Mar 16, 2026 | Mar 13 11:31 PM | Cislini Jeff | Proposed Sale | 2,053 | $99.59 | $204.5K | — | View → |
| Mar 16, 2026 | Mar 13 11:24 PM | Anders Jack | Proposed Sale | 2,134 | $99.59 | $212.5K | — | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 36,000 | $101.23 | $3.6M | 64,424(I) | View → |
| Mar 2, 2026 | Mar 2 9:33 PM | JONATHAN GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $102.02 | $306.1K | — | View → |
| Mar 2, 2026 | Mar 2 9:33 PM | THE REBECCA GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $102.02 | $306.1K | — | View → |
| Mar 2, 2026 | Mar 2 9:32 PM | MARK A GOLDSMITH | Proposed Sale | 30,000 | $102.02 | $3.1M | — | View → |
| Jan 21, 2026 | Jan 23 9:31 PM | Jeff CisliniGeneral Counsel | Sale | 908 | $115.60 | $105.0K | 46,976(D) | View → |
| Jan 21, 2026 | Jan 21 9:23 PM | JEFFREY TODD CISLINI | Proposed Sale | 908 | $116.22 | $105.5K | — | View → |
| Jan 7, 2026 | Jan 7 9:23 PM | MARGARET A HORN | Proposed Sale | 75,000 | $79.85 | $6.0M | — | View → |
| Jan 7, 2026 | Jan 7 9:22 PM | JACK LEE ANDERS | Proposed Sale | 10,000 | $79.85 | $798.5K | — | View → |
| Dec 15, 2025 | Dec 13 2:03 AM | GOLDSMITH MARK A | Proposed Sale | 14,964 | $77.81 | $1.2M | — | View → |
| Dec 15, 2025 | Dec 13 2:00 AM | Kelsey Stephen Michael | Proposed Sale | 5,296 | $77.81 | $412.1K | — | View → |
| Dec 15, 2025 | Dec 13 1:59 AM | Cislini Jeff | Proposed Sale | 2,614 | $77.81 | $203.4K | — | View → |
| Dec 15, 2025 | Dec 13 1:57 AM | Anders Jack | Proposed Sale | 3,017 | $77.81 | $234.8K | — | View → |
| Dec 15, 2025 | Dec 13 1:55 AM | Horn Margaret A | Proposed Sale | 4,711 | $77.81 | $366.6K | — | View → |
| Nov 25, 2025 | Nov 25 9:29 PM | J H GOLDSMITH & M A GOLDSMITHCO-TTEE JONATHAN GOLDSMITH REV TRU/A/D 8/16/2023 | Proposed Sale | 3,000 | $73.66 | $221.0K | — | View → |
| Nov 25, 2025 | Nov 25 9:29 PM | THE REBECCA GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $73.66 | $221.0K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jul 1 10:25 PM | Sushil PatelDirector | Option Exercise | 2,955 | $37.54 | 13,000(D) | View → |
| Jun 24, 2026 | Jun 26 8:10 PM | Jack AndersChief Financial Officer | Option Exercise | 20,000 | $18.56 | 20,600(D) | View → |
| Jun 18, 2026 | Jun 23 9:57 PM | Lorence H. KimDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:52 PM | Alexis BorisyDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Elizabeth M AndersonDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:45 PM | Sandra HorningDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:44 PM | Frank ClyburnDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:43 PM | Sushil PatelDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 18, 2026 | Jun 23 9:42 PM | Flavia BorelliniDirector | Grant/Award | 3,127 | $162.99 | 3,127(D) | View → |
| Jun 17, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 29,600 | $40.74 | 114,275(D) | View → |
| Jun 15, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Option Exercise | 60,400 | $40.74 | 75,052(D) | View → |
| Jun 11, 2026 | Jun 15 8:05 PM | Margaret A HornChief Operating Officer | Option Exercise | 10,000 | $42.45 | 91,194(D) | View → |
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,121 | $33.62 | 106,109(D) | View → |
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
Page 1 of 2
Next →